Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide

被引：0
|
作者：
Follo, M. Y. [1 ]
Mongiorgi, S. [1 ]
Clissa, C. [2 ]
Stoyanova, M. [2 ]
Paolini, S. [2 ]
Quaranta, M. [1 ]
Martinelli, G. [2 ]
Manzoli, L. [1 ]
Cocco, C. [1 ]
Finelli, C. [2 ]
机构：
[1] DIBINEM, Human Anat, Bologna, Italy
[2] DIMES, Hematol, Bologna, Italy
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70061-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-012
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
    Follo, Matilde Y.
    Finelli, Carlo
    Clissa, Cristina
    Mongiorgi, Sara
    Baldazzi, Carmen
    Stanzani, Marta
    Baccarani, Michele
    Cocco, Lucia
    BLOOD, 2013, 122 (21)
  • [2] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [3] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [4] IDENTIFICATION OF BIOMARKERS WHICH COULD PREDICT THE HEMATOLOGICAL RESPONSE OF NON DEL(5Q) LOW-RISK MDS PATIENTS TREATED BY LENALIDOMIDE; THE GFM EXPERIENCE
    Chesnais, V.
    Renneville, A.
    Sardnal, V.
    Delaunay, J.
    Rose, C.
    Stamatoulas, A.
    Beyne-Rauzy, O.
    Fenaux, P.
    Toma, A.
    Drefyus, F.
    Preudhomme, C.
    Kosmider, O.
    Fontenay, M.
    HAEMATOLOGICA, 2014, 99 : 501 - 501
  • [5] TP53 mutations in low-risk MDS patients with isolated del(5q)
    Belickova, M.
    Vesela, J.
    Cermak, J.
    Dostalova, M. M.
    Krejcik, Z.
    Stara, E.
    Zemanova, Z.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2013, 37 : S27 - S28
  • [6] Cytopenias correlate with response to lenalidomide in del 5q MDS patients
    Sekeres, M. A.
    Maciejewski, J. P.
    Giagounidis, A.
    Wride, K.
    Knight, R.
    List, A.
    LEUKEMIA RESEARCH, 2007, 31 : S37 - S38
  • [7] IN VIVO TREATMENT BY LENALIDOMIDE CHANGES THE CLONAL EVOLUTION OF HEMATOPOIETIC STEM PROGENITOR CELLS OF NON DEL(5Q) LOW RISK MDS PATIENTS
    Chesnais, V.
    Renneville, A.
    Toma, A.
    Passet, M.
    Gauthier, A.
    Lefevre, A.
    Delaunay, J.
    Rose, C.
    Stamatoullas, A.
    Beyne-Rauzy, O.
    Fenaux, P.
    Dreyfus, F.
    Preudhomme, C.
    Fontenay, M.
    Kosmider, O.
    HAEMATOLOGICA, 2015, 100 : 16 - 16
  • [8] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
  • [9] Disease progression in del(5q) MDS patients treated with lenalidomide: Analysis of risk factors and long term outcome in 45 patients
    Giagounidis, A.
    Haase, S.
    Lohrbacher, V.
    Schuran, B.
    Heinsch, M.
    Aul, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 85 - 85
  • [10] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
12345